Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
Summary: Antibody–drug conjugates (ADCs) represent a novel and evolving class of antineoplastic agents, constituted by monoclonal antibody linked to biologically active drugs, delivering cytotoxic compounds at the tumor site, reducing the likelihood of systemic exposure and toxicity. They are genera...
Main Authors: | Andrea D’Arienzo, Annarita Verrazzo, Martina Pagliuca, Fabiana Napolitano, Sara Parola, Martina Viggiani, Roberta Caputo, Fabio Puglisi, Mario Giuliano, Lucia Del Mastro, Grazia Arpino, Michelino De Laurentiis, Filippo Montemurro |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-08-01
|
Series: | EClinicalMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537023002900 |
Similar Items
-
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
by: Roberta Caputo, et al.
Published: (2023-08-01) -
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
by: Giampaolo Bianchini, et al.
Published: (2022-02-01) -
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients
by: Federica Miglietta, et al.
Published: (2024-06-01) -
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
by: Mo Wu, et al.
Published: (2022-11-01) -
Progress towards meningitis prevention in the conjugate vaccines era
by: Cristina Aparecida Borges Laval, et al.